The FDA has begun the approval process for leucovorin calcium tablets as a treatment for cerebral folate deficiency (CFD), a neurological condition linked to developmental delays and autistic features. Leucovorin, a form of folate, had previously been discontinued by GSK but is now recognized for its potential in this rare condition. While some administration officials have hyped it as an autism treatment, experts caution that robust evidence of its efficacy and safety in autism remains limited. This initiative marks a pivotal regulatory shift toward repurposing older drugs for neurological indications.